Real-world Clinical Patterns Of Care And Outcomes Among AfME mRCC Patients Receiving Sunitinib as First Line Therapy.

Stopped The study was terminated early due to the inability to recruit the planned number of patients

Conditions

• Metastatic Renal Cell Carcinoma

Interventions

• DRUG: Sunitinib

Sponsor

Pfizer